DIMAP: Disulfiram as a Modulator of Amyloid Precursor Protein-processing
Study Details
Study Description
Brief Summary
A causal therapeutic approach for treatment of Alzheimer's disease has not been established so far. The protein ADAM10 represents a promising target for an A-beta peptide preventing strategy. Treatment of human neuronal cells with Disulfiram, a drug which is used in clinical routine for recrudescence prevention of alcohol dependency, revealed an increased expression of ADAM10. This finding indicates a neuroprotective potential of Disulfiram. The investigators' research purpose aims at the verification of the results obtained in cell culture experiments in the human organism. Therefore, include alcohol addicted patients were included, which take the drug Disulfiram for recrudescence prevention, in our study. Patients are recruited from the patient-collective of the University Medical Center Mainz and the Central Institute for Mental Health Mannheim. Blood samples (max. 5 ml) are taken from the participants before the intake of Disulfiram and about two weeks after treatment. Demographic data are collected (such as age or onset of addiction). Gene expression is analyzed via reverse transcription polymerase chain reaction(RT-PCR) from blood cell-derived messenger ribonucleic acid (mRNA).
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Study Design
Outcome Measures
Primary Outcome Measures
- expression of ADAM10 [August 2016]
expression of ADAM10 in the collected blood samples measured by quantitation of the mRNA amount using RealTime-RT-PCR.
Eligibility Criteria
Criteria
Inclusion Criteria:
ambulant or stationary patients, which receive Disulfiram for recrudescence prevention
Exclusion Criteria:
Diagnosed Alzheimer's dementia Previous Disulfiram treatment less than four weeks before baseline blood collection
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Johannes Gutenberg University Mainz
Investigators
- Principal Investigator: Kristina Endres, Medical Center Johannes Gutenberg University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DIMAP